N@N

Arrayit Corporation: Arrayit Corporation Opens International Marketing Headquarters in Houston

^{Published on 2009-08-12 04:10:35, Last Modified on 2009-08-12 04:10:43 - Market Wire}
 

SUNNYVALE, CA--(Marketwire - August 12, 2009) - Arrayit Corporation (OTCBB: [ ARYC ]), a proprietary life science technology leader, announces the incorporation of Arrayit Diagnostics, Inc., a majority owned Nevada Corporation, to be headquartered in Houston, Texas. The company is currently developing several diagnostic tests for cancer, neurodegenerative disease, and other disease states. Arrayit Diagnostics will promote the commercialization of these tests using Arrayit's microarray platform. By conclusively identifying the genomic and proteomic biomarkers for specific diseases, these tests will allow early stage diagnosis leading to life saving and cost saving treatment protocols.

Arrayit Diagnostics is being put in position to launch one of the most intensive marketing campaigns in Arrayit's twelve year history. Supported by a massive network of 41 international life science and diagnostics distributors located in 38 countries, Arrayit will use this opportunity to expand its worldwide customer base of 10,000 research labs to become a significant global diagnostics company.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 10,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit [ www.arrayit.com ] for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30, 2008.